register

News & Trends - Pharmaceuticals

Gilead and Tango Therapeutics expanding oncology collaboration

Health Industry Hub | August 21, 2020 |

Pharma News: Gilead Sciences and Tango Therapeutics announced an expanded strategic collaboration focused on the discovery, development and commercialisation of innovative targeted immune evasion therapies for patients with cancer.

Under the expanded multi-year collaboration, which builds on an agreement signed in 2018, Tango will continue to leverage its proprietary, CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets. The number of targets covered will expand from five to 15.

Gilead will have options to worldwide rights for programs directed at these targets over the next seven years. Gilead will also have the right to pay option extension fees for Tango to lead activities through early clinical development, to which Gilead will retain its option rights. Tango will have the option to co-develop and co-promote the lead products for up to five programs in the United States.

“Since we signed the original agreement two years ago, we have been very pleased with the productivity of the collaboration and with the quality of scientific discovery that has come from this partnership,” said William A. Lee, PhD, Executive Vice President of Research at Gilead Sciences. “We are looking forward to working with Tango to run additional cancer context dependent screens to identify a broader set of targets based on our immuno-oncology strategy.”

“Gilead has been a valuable strategic partner and strong scientific collaborator and we look forward to advancing programs beyond target validation under this expanded collaboration,” said Barbara Weber, MD, President and Chief Executive Officer of Tango Therapeutics. “The productivity of our platform allows us to generate multiple targets for the collaboration while continuing to discover and develop targets independently, with the shared goal of bringing transformational therapies to patients.”

The collaboration excludes Tango’s lead programs, including one program that is expected to be in investigational new drug (IND) applicatation-enabling studies next year. Tango also retains the rights to identify targets outside the immune evasion space as it continues to build its wholly owned pipeline.

Under the terms of the collaboration, Gilead will make a $125 million upfront payment to Tango and a $20 million equity investment in the company.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.